Search | Page 4 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... lenalidomide , 5- azacitidine , and decitabine . These therapies can be effective in the relief of cytopenias, ...

    Research Article last updated 05/26/2015 - 12:13pm.

  2. Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease

    ... lenalidomide ), and hypomethylating therapy [HMT ( decitabine and 5-azacytidine)]. All patients will eventually lose their ...

    Research Article last updated 05/12/2015 - 9:47am.

  3. More is better: Combination therapies for myelodysplastic syndromes

    ... for MDS; lenalidomide , azacitidine , and decitabine . The role of these agents is to diminish the clinical impact of ...

    Research Article last updated 03/03/2015 - 2:41pm.

  4. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease

    ... lenalidomide ), and hypomethylating therapy [HMT ( decitabine and 5-azacytidine)]. All patients will eventually lose their ...

    Research Article last updated 01/20/2015 - 12:52pm.

  5. Prognostic Factors Associated With Disease Progression and Overall Survival in Patients With Myelodysplastic Syndromes Treated With Decitabine.

    ... AML and survival in 163 patients with MDS treated with decitabine 15 mg/m(2) over 3 hours every 8 hours for 3 days every 6 weeks ... should be considered for other interventions in addition to decitabine treatment. Bone Marrow Diseases:  ...

    Research Article last updated 01/02/2013 - 2:53pm.

  6. Recent developments in myelodysplastic syndromes

    ... (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to ...

    Research Article last updated 10/02/2014 - 10:30am.

  7. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

    ... that achieved response. Treatment of leukemia cells with decitabine resulted in a dose dependent up-regulation of above genes. Exposure to decitabine resulted in partial demethylation of PD-1 in leukemia cell lines and ...

    Research Article last updated 12/17/2013 - 8:32am.

  8. Current therapy of myelodysplastic syndromes.

    ... therapeutic front, the approval of azacitidine , decitabine , and lenalidomide in the last decade was a major ...

    Research Article last updated 09/03/2013 - 12:03pm.

  9. Update on the pharmacotherapy for myelodysplastic syndromes

    ... lenalidomide , azacitidine and decitabine . AREAS COVERED: This review summarizes the major ...

    Research Article last updated 08/21/2014 - 9:23am.

  10. Deacetylase Inhibitors for the Treatment of Myelodysplastic Syndromes

    ... Two demethylating agents, azacitidine and decitabine , are approved for treatment of MDS, though many patients do not ...

    Research Article last updated 08/04/2014 - 8:31am.